Is inflammation a potential target for the treatment of BPH? New research being presented at the 2014 AUA annual meeting may help answer this question.
This article is part of the State of Urology 2014
Dr. KaplanIs inflammation a potential target for the treatment of BPH? New research being presented in Orlando may help answer this question.
“The role of inflammation in the prostate continues to evolve and may be a new target for therapy,” said Steven A. Kaplan, MD, professor of urology at Weill Cornell Medical College, New York.
Updates on new technology for BPH, including the recently approved UroLift system (NeoTract, Inc., Pleasanton, CA) and various new iterations of existing lasers are also expected to draw interest at this year’s meeting, Dr. Kaplan said.
Research on optimizing the patient profile for response to medical therapy for BPH and outcomes of LUTS therapy and concomitant hypogonadism therapy and the association between other comorbid factors (eg, obesity and cardiovascular disease) will be hot topics as well, he noted.
Here is Dr. Kaplan’s list of the best abstracts from the podium and poster sessions:
PD25-01: The AUA Clinical Practice Guideline for the Management of LUTS/BPH: Do We Practice What the Guideline Preaches?
Gregory B. Auffenberg
PD23-06: Change in Sexual Function in Men With LUTS/BPH Associated with Long-term Treatment with Doxazosin, Finasteride, and Combined Therapy
R. Charles Welliver, Jr.
PD26-06: Greenlight XPS-180W Laser Vaporization of the Prostate for Benign Prostatic Hyperplasia: A Global, Multi-center Study Including 1053 Patients, Analysis of Complication Rates and Outcomes at 2 Years According to Prostate Size
PD26-09: Transurethral Water Vapor Therapy for BPH; 1-year Clinical Results of the First-in-Man and Rezum I Clinical Trials Using the Rezum System
PD26-12: Use of Medical Therapy and Success of Laser Surgery and TURP for BPH
MP71-01: Comparative Outcomes of Open and Minimally Invasive Simple Prostatectomy for Symptomatic Benign Prostatic Hyperplasia
MP71-08: Two Year Durability of the Prostatic Urethral Lift: Multi-center Prospective Study
Claus G. Roehrborn
MP71-16: Prospective Randomized Controlled Trial Comparing Greenlight (GL) 180-W XPS PVP and Transurethral Resection of the Prostate (The Goliath Study): One Year Follow-up By Prostate Size
Subscribe to Urology Times to get monthly news from the leading news source for urologists.